Zobrazeno 1 - 10
of 35
pro vyhledávání: '"Axel Choidas"'
Autor:
Patricia Johansson, Laura Dierichs, Ludger Klein-Hitpass, Anke K. Bergmann, Michael Möllmann, Sascha Menninger, Peter Habenberger, Bert Klebl, Jens T. Siveke, Ulrich Dührsen, Axel Choidas, Jan Dürig
Publikováno v:
Therapeutic Advances in Hematology, Vol 11 (2020)
T-cell prolymphocytic leukemia (T-PLL) is an aggressive malignancy characterized by chemotherapy resistance and a median survival of less than 2 years. Here, we investigated the pharmacological effects of the novel highly specific cyclin-dependent ki
Externí odkaz:
https://doaj.org/article/dbaad95c53fa476da2bd0fedf8b2e735
Autor:
Johannes Brägelmann, Marcel A. Dammert, Felix Dietlein, Johannes M. Heuckmann, Axel Choidas, Stefanie Böhm, André Richters, Debjit Basu, Verena Tischler, Carina Lorenz, Peter Habenberger, Zhizhou Fang, Sandra Ortiz-Cuaran, Frauke Leenders, Jan Eickhoff, Uwe Koch, Matthäus Getlik, Martin Termathe, Muhammad Sallouh, Zoltán Greff, Zoltán Varga, Hyatt Balke-Want, Christopher A. French, Martin Peifer, H. Christian Reinhardt, László Örfi, György Kéri, Sascha Ansén, Lukas C. Heukamp, Reinhard Büttner, Daniel Rauh, Bert M. Klebl, Roman K. Thomas, Martin L. Sos
Publikováno v:
Cell Reports, Vol 20, Iss 12, Pp 2833-2845 (2017)
Kinase inhibitors represent the backbone of targeted cancer therapy, yet only a limited number of oncogenic drivers are directly druggable. By interrogating the activity of 1,505 kinase inhibitors, we found that BRD4-NUT-rearranged NUT midline carcin
Externí odkaz:
https://doaj.org/article/65260813004b4d5e8d198b9f59d2baa6
Autor:
Blaž Andlovic, Geronimo Heilmann, Sabrina Ninck, Sebastian A. Andrei, Federica Centorrino, Yusuke Higuchi, Nobuo Kato, Luc Brunsveld, Michelle Arkin, Sascha Menninger, Axel Choidas, Alexander Wolf, Bert Klebl, Farnusch Kaschani, Markus Kaiser, Jan Eickhoff, Christian Ottmann
Publikováno v:
Cell Chemical Biology.
The natural product family of the fusicoccanes (FCs) has been shown to display anti-cancer activity, especially when combined with established therapeutic agents. FCs stabilize 14-3-3 protein-protein interactions (PPIs). Here, we tested combinations
Autor:
Stephan Jeuken, Oleksandr Shkura, Marc Röger, Victoria Brickau, Axel Choidas, Carsten Degenhart, Daniel Gülden, Bert Klebl, Uwe Koch, Raphael Stoll, Jürgen Scherkenbeck
Publikováno v:
ChemMedChem. 17
Ras proteins are implicated in some of the most common life-threatening cancers. Despite intense research during the past three decades, progress towards small-molecule inhibitors of mutant Ras proteins still has been limited. Only recently has signi
Publikováno v:
Cancers 14(18), 4386 (2022). doi:10.3390/cancers14184386
Cancers 14(18), 4386 (2022). doi:10.3390/cancers14184386
Published by MDPI, Basel
Published by MDPI, Basel
Autor:
Won-Gyun Ahn, Yeejin Jeon, Yeong-In Yang, Jaeseung Kim, Seung-Joo Lee, Uwe Koch, Gunther Zischinsky, Axel Choidas, Ayesha Pasha, Bert Klebl, Robert Huber, Michael Hamacher, Kiyean Nam
Publikováno v:
Cancer Research. 82:416-416
The existing proteasome inhibitors, such as bortezomib and ixazomib, are effective in multiple myeloma, but have little activity against solid tumors. These are covalent boronic acid-based compounds and are associated with undesired side effects, mai
Autor:
Ulrich Lücking, Jan Dürig, Michael Möllmann, Axel Choidas, Joachim R. Göthert, Roze Imsak, Ulrich Dührsen, Anke Unger, Carsten Schultz-Fademrecht, Maria Göbel, Arne Scholz, Stefanie Kesper, Bert Klebl, Jan Eickhoff, Matthias Baumann
Publikováno v:
Oncotarget
Onset of progression even during therapy with novel drugs remains an issue in chronic lymphocytic leukemia (CLL). Thus, there is ongoing demand for novel agents. Approaches targeting cyclin-dependent kinases (CDK) have reached the clinical trial stag
Identification of an (−)-englerin A analogue, which antagonizes (−)-englerin A at TRPC1/4/5 channels
Autor:
Mathias Christmann, Peter Nussbaumer, Herbert Waldmann, Klaus Dinkel, Bert Klebl, David J. Beech, Peter Habenberger, Hussein N. Rubaiy, Axel Choidas, Tobias Seitz, Sven Hahn
Publikováno v:
British Journal of Pharmacology. 175:830-839
Background and Purpose: (−)‐Englerin A (EA) is a potent cytotoxic agent against renal carcinoma cells. It achieves its effects by activation of transient receptor potential canonical (TRPC)4/TRPC1 heteromeric channels. It is also an agonist at ch
Autor:
Bert Klebl, Hans R. Schöler, Herbert Waldmann, Matthias Baumann, Gisbert Schneider, Jared Sterneckert, Lea Kremer, Susanne Kordes, Peter Habenberger, Carsten Schultz-Fademrecht, Slava Ziegler, Axel Choidas
Publikováno v:
Angewandte Chemie International Edition. 56:13021-13025
Cell-based assays enable monitoring of small-molecule bioactivity in a target-agnostic manner and help uncover new biological mechanisms. Subsequent identification and validation of the small-molecule targets, typically employing proteomics technique
Autor:
Felix Dietlein, Roman K. Thomas, Martin Peifer, Daniel Rauh, Zoltán Varga, Johannes M. Heuckmann, Axel Choidas, Johannes Brägelmann, Jan Eickhoff, Carina Lorenz, Hyatt Balke-Want, György Kéri, Zhizhou Fang, Stefanie Böhm, Zoltán Greff, Muhammad Sallouh, Martin Termathe, Reinhard Büttner, Debjit Basu, Christopher A. French, Uwe Koch, Frauke Leenders, André Richters, Martin L. Sos, Verena Tischler, Bert Klebl, Sascha Ansén, Peter Habenberger, Laszlo Orfi, Matthäus Getlik, Sandra Ortiz-Cuaran, Marcel A. Dammert, Lukas C. Heukamp, H. Christian Reinhardt
Publikováno v:
Cell Reports
Cell Reports, Vol 20, Iss 12, Pp 2833-2845 (2017)
Cell Reports, Vol 20, Iss 12, Pp 2833-2845 (2017)
Summary Kinase inhibitors represent the backbone of targeted cancer therapy, yet only a limited number of oncogenic drivers are directly druggable. By interrogating the activity of 1,505 kinase inhibitors, we found that BRD4-NUT-rearranged NUT midlin